Notes
National Institute for Health and Care Excellence
National Health Service
Reference
NICE. Appraisal consultation document: Daratumumab monotherapy for treating relapsed and refractory multiple myeloma. Internet Document : 17 Mar 2017. Available from: URL: https://www.nice.org.uk/guidance/indevelopment/gid-ta10076/documents
Rights and permissions
About this article
Cite this article
Daratumumab not recommended for MM in NICE draft guidance. PharmacoEcon Outcomes News 774, 32 (2017). https://doi.org/10.1007/s40274-017-3856-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-017-3856-4